Global Recombinant FSH Injections Market Growth 2024-2030

Publication ID:

LPI04242185

Publication Date:

April 18, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Follicle Stimulating Hormone (FSH) injections are pharmaceutical preparations containing the hormone FSH, a crucial component in the regulation of reproductive processes. FSH is produced by the pituitary gland and plays a key role in the stimulation of ovarian follicles in females and sperm production in males. FSH injections are commonly used in assisted reproductive technologies, such as in vitro fertilization (IVF), to enhance the development and maturation of multiple follicles in the ovaries. In fertility treatments, these injections help regulate and stimulate the ovaries to produce more eggs, increasing the chances of successful fertilization and pregnancy.
Human follicle stimulating hormone (FSH) includes urinary human follicle stimulating hormone (uFSH) and recombinant FSH (rFSH). According to expert consensus, recombinant follicle-stimulating hormone is available in two dosage forms: powder injection and water injection.
The global Recombinant FSH Injections market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淩ecombinant FSH Injections Industry Forecast鈥� looks at past sales and reviews total world Recombinant FSH Injections sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant FSH Injections sales for 2024 through 2030. With Recombinant FSH Injections sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant FSH Injections industry.
This Insight Report provides a comprehensive analysis of the global Recombinant FSH Injections landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant FSH Injections portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant FSH Injections market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant FSH Injections and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant FSH Injections.
The fertility preservation and infertility treatment market has witnessed significant growth in recent years, driven by factors such as increasing infertility rates, delayed pregnancies, advancements in assisted reproductive technologies (ART), and growing awareness. Fertility preservation technologies, including egg freezing and sperm banking, have gained popularity among individuals seeking to preserve their reproductive potential. In the infertility treatment segment, in vitro fertilization (IVF), intrauterine insemination (IUI), and other ART procedures have become mainstream options. Future developments are anticipated in areas such as personalized medicine, gene editing technologies, and improved success rates in ART procedures. The market is likely to see ongoing advancements, innovations, and collaborations aimed at addressing infertility challenges and expanding the range of options available to individuals and couples.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant FSH Injections market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Powder
Liquid
Segmentation by application
IVF and Embryo Transfer
Infertility Treatment
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gonal-F (Merck)
Follistim (Organon)
Bravelle (Ferring)
Menopur (Ferring)
Fostimon (IBSA)
Puregon (Organon)
BEMFOLA (Gedeon Richter)
Follitrope (LG Chem)
GenSci
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant FSH Injections market?
What factors are driving Recombinant FSH Injections market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant FSH Injections market opportunities vary by end market size?
How does Recombinant FSH Injections break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant FSH Injections Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant FSH Injections by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant FSH Injections by Country/Region, 2019, 2023 & 2030
2.2 Recombinant FSH Injections Segment by Type
2.2.1 Powder
2.2.2 Liquid
2.3 Recombinant FSH Injections Sales by Type
2.3.1 Global Recombinant FSH Injections Sales Market Share by Type (2019-2024)
2.3.2 Global Recombinant FSH Injections Revenue and Market Share by Type (2019-2024)
2.3.3 Global Recombinant FSH Injections Sale Price by Type (2019-2024)
2.4 Recombinant FSH Injections Segment by Application
2.4.1 IVF and Embryo Transfer
2.4.2 Infertility Treatment
2.5 Recombinant FSH Injections Sales by Application
2.5.1 Global Recombinant FSH Injections Sale Market Share by Application (2019-2024)
2.5.2 Global Recombinant FSH Injections Revenue and Market Share by Application (2019-2024)
2.5.3 Global Recombinant FSH Injections Sale Price by Application (2019-2024)
3 Global Recombinant FSH Injections by Company
3.1 Global Recombinant FSH Injections Breakdown Data by Company
3.1.1 Global Recombinant FSH Injections Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant FSH Injections Sales Market Share by Company (2019-2024)
3.2 Global Recombinant FSH Injections Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant FSH Injections Revenue by Company (2019-2024)
3.2.2 Global Recombinant FSH Injections Revenue Market Share by Company (2019-2024)
3.3 Global Recombinant FSH Injections Sale Price by Company
3.4 Key Manufacturers Recombinant FSH Injections Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant FSH Injections Product Location Distribution
3.4.2 Players Recombinant FSH Injections Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Recombinant FSH Injections by Geographic Region
4.1 World Historic Recombinant FSH Injections Market Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant FSH Injections Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant FSH Injections Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant FSH Injections Market Size by Country/Region (2019-2024)
4.2.1 Global Recombinant FSH Injections Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant FSH Injections Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant FSH Injections Sales Growth
4.4 APAC Recombinant FSH Injections Sales Growth
4.5 Europe Recombinant FSH Injections Sales Growth
4.6 Middle East & Africa Recombinant FSH Injections Sales Growth
5 Americas
5.1 Americas Recombinant FSH Injections Sales by Country
5.1.1 Americas Recombinant FSH Injections Sales by Country (2019-2024)
5.1.2 Americas Recombinant FSH Injections Revenue by Country (2019-2024)
5.2 Americas Recombinant FSH Injections Sales by Type
5.3 Americas Recombinant FSH Injections Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant FSH Injections Sales by Region
6.1.1 APAC Recombinant FSH Injections Sales by Region (2019-2024)
6.1.2 APAC Recombinant FSH Injections Revenue by Region (2019-2024)
6.2 APAC Recombinant FSH Injections Sales by Type
6.3 APAC Recombinant FSH Injections Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant FSH Injections by Country
7.1.1 Europe Recombinant FSH Injections Sales by Country (2019-2024)
7.1.2 Europe Recombinant FSH Injections Revenue by Country (2019-2024)
7.2 Europe Recombinant FSH Injections Sales by Type
7.3 Europe Recombinant FSH Injections Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant FSH Injections by Country
8.1.1 Middle East & Africa Recombinant FSH Injections Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant FSH Injections Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant FSH Injections Sales by Type
8.3 Middle East & Africa Recombinant FSH Injections Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant FSH Injections
10.3 Manufacturing Process Analysis of Recombinant FSH Injections
10.4 Industry Chain Structure of Recombinant FSH Injections
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant FSH Injections Distributors
11.3 Recombinant FSH Injections Customer
12 World Forecast Review for Recombinant FSH Injections by Geographic Region
12.1 Global Recombinant FSH Injections Market Size Forecast by Region
12.1.1 Global Recombinant FSH Injections Forecast by Region (2025-2030)
12.1.2 Global Recombinant FSH Injections Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant FSH Injections Forecast by Type
12.7 Global Recombinant FSH Injections Forecast by Application
13 Key Players Analysis
13.1 Gonal-F (Merck)
13.1.1 Gonal-F (Merck) Company Information
13.1.2 Gonal-F (Merck) Recombinant FSH Injections Product Portfolios and Specifications
13.1.3 Gonal-F (Merck) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Gonal-F (Merck) Main Business Overview
13.1.5 Gonal-F (Merck) Latest Developments
13.2 Follistim (Organon)
13.2.1 Follistim (Organon) Company Information
13.2.2 Follistim (Organon) Recombinant FSH Injections Product Portfolios and Specifications
13.2.3 Follistim (Organon) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Follistim (Organon) Main Business Overview
13.2.5 Follistim (Organon) Latest Developments
13.3 Bravelle (Ferring)
13.3.1 Bravelle (Ferring) Company Information
13.3.2 Bravelle (Ferring) Recombinant FSH Injections Product Portfolios and Specifications
13.3.3 Bravelle (Ferring) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bravelle (Ferring) Main Business Overview
13.3.5 Bravelle (Ferring) Latest Developments
13.4 Menopur (Ferring)
13.4.1 Menopur (Ferring) Company Information
13.4.2 Menopur (Ferring) Recombinant FSH Injections Product Portfolios and Specifications
13.4.3 Menopur (Ferring) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Menopur (Ferring) Main Business Overview
13.4.5 Menopur (Ferring) Latest Developments
13.5 Fostimon (IBSA)
13.5.1 Fostimon (IBSA) Company Information
13.5.2 Fostimon (IBSA) Recombinant FSH Injections Product Portfolios and Specifications
13.5.3 Fostimon (IBSA) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Fostimon (IBSA) Main Business Overview
13.5.5 Fostimon (IBSA) Latest Developments
13.6 Puregon (Organon)
13.6.1 Puregon (Organon) Company Information
13.6.2 Puregon (Organon) Recombinant FSH Injections Product Portfolios and Specifications
13.6.3 Puregon (Organon) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Puregon (Organon) Main Business Overview
13.6.5 Puregon (Organon) Latest Developments
13.7 BEMFOLA (Gedeon Richter)
13.7.1 BEMFOLA (Gedeon Richter) Company Information
13.7.2 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Product Portfolios and Specifications
13.7.3 BEMFOLA (Gedeon Richter) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 BEMFOLA (Gedeon Richter) Main Business Overview
13.7.5 BEMFOLA (Gedeon Richter) Latest Developments
13.8 Follitrope (LG Chem)
13.8.1 Follitrope (LG Chem) Company Information
13.8.2 Follitrope (LG Chem) Recombinant FSH Injections Product Portfolios and Specifications
13.8.3 Follitrope (LG Chem) Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Follitrope (LG Chem) Main Business Overview
13.8.5 Follitrope (LG Chem) Latest Developments
13.9 GenSci
13.9.1 GenSci Company Information
13.9.2 GenSci Recombinant FSH Injections Product Portfolios and Specifications
13.9.3 GenSci Recombinant FSH Injections Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 GenSci Main Business Overview
13.9.5 GenSci Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂